Get the Stockscreener App
11.42
2.64%
-0.31
After Hours:
11.42
Korro Bio Inc stock is traded at $11.42, with a volume of 84,957.
It is down -2.64% in the last 24 hours and down -35.66% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$11.73
Open:
$11.71
24h Volume:
84,957
Relative Volume:
0.86
Market Cap:
$107.23M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-1.1269
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
-17.25%
1M Performance:
-35.66%
6M Performance:
-78.06%
1Y Performance:
-77.27%
1-Day Range:
$11.00
$11.98
1-Week Range:
$11.00
$14.20
52-Week Range:
$11.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
11.42 | 129.59M | 0 | -81.17M | -82.84M | -10.13 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc. (NASDAQ:KRRO) Shares Purchased by BNP Paribas Financial Markets - Defense World
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com Nigeria
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Boosted by Northern Trust Corp - Defense World
Brokers Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Balyasny Asset Management L.P. Makes New Investment in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio Leadership Takes Stage at Three Major Healthcare Conferences: RBC, Jefferies, and Goldman Sachs - Stock Titan
Korro Bio (KRRO) Rating and Price Target Maintained by Chardan C - GuruFocus
Oppenheimer Adjusts Price Target for Korro Bio (KRRO) Amid Secto - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintai - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintains Rating | KRRO Stock News - GuruFocus
Oppenheimer Adjusts Korro Bio Price Target to $90 From $155, Maintains Outperform Rating - marketscreener.com
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Q2 Earnings Forecast for Korro Bio Issued By HC Wainwright - Defense World
HC Wainwright Cuts Korro Bio (NASDAQ:KRRO) Price Target to $100.00 - Defense World
HC Wainwright Comments on Korro Bio FY2026 Earnings - Defense World
Wells Fargo & Company MN Raises Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
10,384 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Barclays PLC - Defense World
10,347 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Raymond James Financial Inc. - Defense World
Korro Bio (KRRO) Price Target Cut Amid Strategic Adjustments | K - GuruFocus
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright - Yahoo Finance
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Buy” by Analysts - Defense World
Korro Bio Reports Q1 2025 Financial Results - TipRanks
Korro Bio stock price target lowered to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Korro Bio stock price target lowered to $100 at H.C. Wainwright - Investing.com Nigeria
4 more biotechs cut staff amid market tumult - BioPharma Dive
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs - Endpoints News
Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership - Fierce Biotech
Korro Bio (KRRO) Analyst Rating Update: Price Target Lowered | K - GuruFocus
Korro Bio (KRRO) Price Target Reduced, Buy Rating Maintained | K - GuruFocus
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Korro (KRRO) Surpasses Q1 Revenue Expectations Amid Promising Cl - GuruFocus
Korro Bio Announces Strategic Workforce Reduction Plan - TipRanks
Korro Bio, Inc. SEC 10-Q Report - TradingView
Korro Bio, Inc. Reports Q1 2025 Financial Results and Updates on KRRO-110 Development for Alpha-1 Antitrypsin Deficiency - Nasdaq
JPMorgan Chase & Co. Sells 9,537 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Legal & General Group Plc Raises Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Analysts Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Cantor Fitzgerald Upgrades Korro Bio (NASDAQ:KRRO) to Strong-Buy - Defense World
Cantor Fitzgerald sets $74 target on Korro Bio stock with Overweight rating - Investing.com India
Korro Bio (KRRO) Receives Overweight Rating and $74 Price Target - GuruFocus
Korro Bio (KRRO) Receives Overweight Rating and $74 Price Target | KRRO Stock News - GuruFocus
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Chardan Capital - Defense World
Chardan sets $25 target on Korro Bio stock with Buy rating - Investing.com Australia
Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - Nasdaq
Chardan Initiates Korro Bio at Buy With $25 Price Target - marketscreener.com
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by Wellington Management Group LLP - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):